Lebrikizumab Improves Itch, Itch Interference on Sleep, and Skin Pain in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

In the open-label ADapt trial, lebrikizumab demonstrated significant improvements in managing symptoms of AD like itch, sleep disruption due to itching, and skin pain in patients who had previously been treated with dupilumab. For those who discontinued dupilumab due to insufficient response, lebrikizumab offered clinically meaningful results: by week 16, half of these patients experienced a 4-point or greater improvement in itch severity, while more than 65% saw at least a 3-point reduction in their pruritus score, showcasing its effectiveness in providing relief for persistent symptoms.

Click here for a link to the original poster.

Elevate-Derm Alliance Editorial Board